ABL1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-1, of which 2 are open and 0 are closed. Of the trials that contain AFF1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains BCR status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains ELL status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains KIT status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-1, of which 2 are open and 0 are closed. Of the trials that contain KMT2A status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-1, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-1, of which 2 are open and 0 are closed. Of the trials that contain RPN1 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [3].